Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation (New York, N.Y.) N.Y.), 2019-08, Vol.140 (6), p.443-445
1. Verfasser:	Packer, Milton
Format:	Artikel
Sprache:	eng
Schlagworte:	Benzhydryl Compounds - pharmacology Benzhydryl Compounds - therapeutic use Blood Volume - drug effects Death, Sudden, Cardiac - etiology Death, Sudden, Cardiac - prevention & control Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - physiopathology Diabetic Cardiomyopathies - complications Diabetic Cardiomyopathies - physiopathology Diuretics - therapeutic use Glucose - metabolism Glucosides - pharmacology Glucosides - therapeutic use Heart Failure - drug therapy Heart Failure - etiology Heart Failure - physiopathology Hospitalization - statistics & numerical data Humans Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Kidney Tubules, Proximal - drug effects Kidney Tubules, Proximal - metabolism Multicenter Studies as Topic Myocardial Infarction - etiology Myocardial Infarction - prevention & control Natriuresis - drug effects Randomized Controlled Trials as Topic Sodium-Glucose Transporter 2 - physiology Sodium-Glucose Transporter 2 Inhibitors - pharmacology Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Sodium-Hydrogen Exchanger 1 - antagonists & inhibitors Stroke - etiology Stroke - prevention & control Stroke Volume - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:
ISSN:	0009-7322 1524-4539
DOI:	10.1161/CIRCULATIONAHA.119.040909